ArticleLeukemia2017

Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.

H Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.